Date: 2014-09-03
Type of information: Production agreement
Compound: recombinant human IgG1 bispecific antibody
Company: CMC Biologics (Denmark) Zymeworks (Canada)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details: * On September 3, 2014, CMC Biologics, global leader in process development and contract manufacturing, and Zymeworks Inc., a Canadian biotherapeutics company and a world leader in the development of antibody therapeutics, have entered into a Master Services Agreement for process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric) antibody. \"As we advance our lead Azymetric™ oncology program and first therapeutic built on our proprietary ZymeCAD™ platform, choosing a contract partner with a track record of success in development and manufacturing is critical,\" said Ali Tehrani, PhD, President and CEO of Zymeworks. \"Our collaboration with CMC Biologics helps position us to move our oncology program into clinical trials for the treatment of breast cancer and other solid tumors, as well as subsequent therapeutic candidates targeted towards hematological cancers such as leukemia and lymphoma.\"
Financial terms:
Latest news:
